Northstar Wealth Partners LLC trimmed its holdings in Pfizer, Inc. (NYSE:PFE) by 3.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 62,392 shares of the biopharmaceutical company’s stock after selling 2,088 shares during the quarter. Pfizer comprises 1.9% of Northstar Wealth Partners LLC’s portfolio, making the stock its 11th biggest holding. Northstar Wealth Partners LLC’s holdings in Pfizer were worth $2,084,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in PFE. Northstar Group Inc. increased its position in Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 35 shares during the period. River Wealth Advisors LLC increased its position in Pfizer by 0.3% in the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after purchasing an additional 55 shares during the period. Meridian Wealth Management LLC increased its position in Pfizer by 0.5% in the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after purchasing an additional 57 shares during the period. Stone House Investment Management LLC increased its position in Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 66 shares during the period. Finally, Naples Global Advisors LLC increased its position in Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after purchasing an additional 79 shares during the period. 69.01% of the stock is owned by institutional investors and hedge funds.

PFE has been the subject of a number of research reports. UBS Group AG (USA) reiterated a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a research report on Monday, July 31st. Cowen and Company set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, July 10th. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets restated a “buy” rating and set a $37.00 target price on shares of Pfizer in a research report on Wednesday, September 6th. Finally, Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price for the company in a research report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $38.35.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/pfizer-inc-pfe-shares-sold-by-northstar-wealth-partners-llc/1677153.html.

In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the sale, the insider now owns 74,506 shares in the company, valued at approximately $2,436,346.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the sale, the executive vice president now owns 117,432 shares in the company, valued at approximately $4,186,450.80. The disclosure for this sale can be found here. Insiders sold a total of 389,621 shares of company stock worth $13,298,598 in the last 90 days. Company insiders own 0.06% of the company’s stock.

Shares of Pfizer, Inc. (NYSE:PFE) opened at $35.55 on Friday. The company has a market cap of $210.89 billion, a P/E ratio of 14.18, a P/E/G ratio of 2.45 and a beta of 1.01. The company has a quick ratio of 1.06, a current ratio of 1.34 and a debt-to-equity ratio of 0.58.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a return on equity of 25.67% and a net margin of 18.69%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.61 EPS. equities analysts forecast that Pfizer, Inc. will post 2.59 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.60%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s payout ratio is 79.01%.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.